FindTrial
Sign In

Precision dosing of intravenous infusion combined with aerosol inhalation of polymyxin E in critically ill patients based on physiological mechanisms and population approach

Precision dosing of intravenous infusion combined with aerosol inhalation of polymyxin E in critically ill patients based on physiological mechanisms and population approach

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065666
Enrollment
Unknown
Registered
2022-11-11
Start date
2022-11-11
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-negative bacteria infection

Interventions

Patients with severe pulmonary infection treated with polymyxin E:None

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Critically ill patients diagnosed with Gram-negative bacterial infection; 3. Polymyxin E has been administered continuously for more than 2 days, and the plasma concentration reaches a steady state; 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: Patients allergic to polymyxin E.

Design outcomes

Primary

MeasureTime frame
Plasma concentration;ELF concentration;—

Countries

China

Contacts

Public ContactPei Qi

The Third Xiangya Hospital of Central South University

ygp9880@126.com+86 13170419804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026